Pharmaceutical Analysis & Statistics, October 2014

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

  • All
    • Global Data

All regions

You might be interested in: therapeutics, drug, cancer, more »

1-30 of about 6 000 reports

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 Summary The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the ...

  • Industries : Pathology
  • Countries : United States
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018 Summary The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the ...

  • Industries : Therapy
  • Countries : United States, World
PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, World, Europe
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : Spain, France, Italy, Germany, United Kingdom, Europe, World
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : China
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Japan
PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Australia
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Japan
EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 Summary Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascula ...

  • Industries : Pathology
  • Countries : Germany, Japan, China, World, United States
EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 Summary Allergic conjunctivitis is an inflammation of the eye resulting from an allergic reaction to allergy causing substances (external ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany
EpiCast Report: Asthma - Epidemiology Forecast to 2023

EpiCast Report: Asthma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Asthma - Epidemiology Forecast to 2023 Summary Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term ...

  • Industries : Pathology
EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that ...

  • Industries : Pathology
  • Countries : Japan, World
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • August 2014
  • by Global Data

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part ...

  • Industries : Pathology
  • Countries : Japan, China, World, United States, Spain, Italy, France, Germany
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Dulera (Asthma) - Forecast and Market Analysis to 2023

Dulera (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dulera (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dulera (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : World, United States
Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flutiform (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
About 57 000 reports

Download Unlimited Documents from Trusted Public Sources

E-cigarette Market Forecast in the UK

  • Advertising of E-cigarettes
  • October 2014
    9 pages
  • E-cigarette  

    Smoking Treatme...  

  • United Kingdom  

    Europe  

View report >

Medication Market

October 2014

94 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

AstraZeneca PLC

United Kingdom

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.